GUIDELINE

Abstract submission is closed.

The abstract acceptance has been announced on email. If you have not received an email, please check your junk or spam folder, or contact us at asnos2022abstract@gmail.com

Abstract Submission Period

ABSTRACT SUBMISSION OPENS

1 JULY 2022

ABSTRACT SUBMISSION DEADLINE

15 SEPTEMBER 2022

ABSTRACT ACCEPTANCE ANNOUNCEMENT

16 SEPTEMBER 2022

* Dates are based on Thailand Standard Time, 23:59 (GMT+7).

There are two types of Abstract submission for the ASNOS 2022

Walsh in Asia submission
Scientific paper submission

*The abstract committee may recommend changing scientific abstract type based on the content of the abstract.

1. Walsh in Asia (Neuro-oph - Radiology - Pathology interesting case conference)

Abstracts selected by the committee will be presented as oral presentations during the Walsh in Asia symposium (date will be updated soon). Abstracts that are not selected for Walsh in Asia symposium will be offered the opportunity to present as a ePoster presentation.

Abstracts selected by the committee will be presented as oral presentations during the Walsh in Asia symposium (date will be updated soon). Abstracts that are not selected for Walsh in Asia symposium will be offered the opportunity to present as a ePoster presentation.

WALSH IN ASIA ABSTRACT PREPARATION GUIDELINES:

Abstracts must be in English.
All abstracts should be submitted online via submission system.
The title should not reveal the diagnosis but should be relevant to the case material.
Six items needed:
- Summary of Clinical history & exam finding;
- Case abstract with references
- Case Dilemmas – e.g. difficult decision making, incorrect diagnosis;
- Two/Three teaching points;
- Representative Radiology Images (the images will be requested later);
- Representative Pathology Images (the images will be requested later);
Please crop out any patient identifiers in any images.
Glass pathology slides may be requests based on the pathologist’s review.
Full imaging may be requested based on the radiologist’s review.

Abstracts must be in English.
All abstracts should be submitted online via submission system.
The title should not reveal the diagnosis but should be relevant to the case material.
Six items needed:
- Summary of Clinical history & exam finding;
- Case abstract with references
- Case Dilemmas – e.g. difficult decision making, incorrect diagnosis;
- Two/Three teaching points;
- Representative Radiology Images (the images will be requested later);
- Representative Pathology Images (the images will be requested later);
Please crop out any patient identifiers in any images.
Glass pathology slides may be requests based on the pathologist’s review.
Full imaging may be requested based on the radiologist’s review.

2. Scientific Paper (Case Reports or Other)

Authors must select whether they would like the abstract to be considered for platform presentation or poster presentation. Abstracts accepted for platform presentation will be presented during 1 of 2 Free Paper sessions during the ASNOS 2022 congress. Abstracts not accepted for platform presentation will be offered the opportunity to be presented as poster presentation.
The presenting author must be a registered participant for the ASNOS 2022 congress.
ASNOS 2022 congress will not accept abstracts that have been accepted for publication at the time of submission.
Advertising or any form of commercial solicitation is not allowed in ASNOS abstract presentations without prior approval from the ASNOS 2022 congress.

Authors must select whether they would like the abstract to be considered for platform presentation or poster presentation. Abstracts accepted for platform presentation will be presented during 1 of 2 Free Paper sessions during the ASNOS 2022 congress. Abstracts not accepted for platform presentation will be offered the opportunity to be presented as poster presentation.
The presenting author must be a registered participant for the ASNOS 2022 congress.
ASNOS 2022 congress will not accept abstracts that have been accepted for publication at the time of submission.
Advertising or any form of commercial solicitation is not allowed in ASNOS abstract presentations without prior approval from the ASNOS 2022 congress.

SCIENTIFIC PAPER (Case reports or other) ABSTRACT PREPARATION GUIDELINES:

Abstracts must be in English.
All abstracts should be submitted online via submission system.
The title should be as brief as possible but long enough to indicate clearly the nature of the study. Capitalize the first letter of each word.
The word limit for all abstracts is 300 words NOT including Title, Authors, Affiliations, Disclosures and References.
Abstracts will be reproduced exactly as submitted. Please edit your abstract carefully to avoid errors and misspellings.
Title: Title should be as brief as possible but long enough to give clear nature of the study. Capitalize the first letter of each word.
Author(s): Provide the full name of every author, including degrees. but omit titles or institutional appointments.
Institution(s): Indicate the name and address of the institution(s) where the research work was carried out.
Abstracts should be arranged in the following format:

Abstracts must be in English.
All abstracts should be submitted online via submission system.
The title should be as brief as possible but long enough to indicate clearly the nature of the study. Capitalize the first letter of each word.
The word limit for all abstracts is 300 words NOT including Title, Authors, Affiliations, Disclosures and References.
Abstracts will be reproduced exactly as submitted. Please edit your abstract carefully to avoid errors and misspellings.
Title: Title should be as brief as possible but long enough to give clear nature of the study. Capitalize the first letter of each word.
Author(s): Provide the full name of every author, including degrees. but omit titles or institutional appointments.
Institution(s): Indicate the name and address of the institution(s) where the research work was carried out.
Abstracts should be arranged in the following format:

CASE REPORTS

Abstracts should state briefly and clearly describe the case(s) and conclusions including interesting features or teaching points
Introduction – Concisely state relevant background information.
Description – Include relevant case data.
Conclusions – Give emphasis on the uniqueness of the case and its key learning points.

Abstracts should state briefly and clearly describe the case(s) and conclusions including interesting features or teaching points
Introduction – Concisely state relevant background information.
Description – Include relevant case data.
Conclusions – Give emphasis on the uniqueness of the case and its key learning points.

NON-CASE REPORTS (OTHER)

Abstracts should state briefly and clearly the purpose, methods, results and conclusions of the study.
Objective – Concisely state purpose and relevant background information.
Methods – Describe study design, how subjects were selected, and the number of subjects and/or observations included in the study.
Results – State in a logical sequence, include quantitative descriptions and/or comparisons.
Conclusions – State new and/or important feature of the study, and conclusions drawn from it
Abbreviations, acronyms, and symbols should be defined the first time they are used. Place the abbreviation in parentheses after the full word.
Use generic names of drugs.
Proprietary and/or financial interests in any products (or competing products) described in the abstract must be disclosed.
The Scientific Program Subcommittee reserves the right to accept or reject the abstracts submitted for platform or poster presentation as it deems appropriate.

Abstracts should state briefly and clearly the purpose, methods, results and conclusions of the study.
Objective – Concisely state purpose and relevant background information.
Methods – Describe study design, how subjects were selected, and the number of subjects and/or observations included in the study.
Results – State in a logical sequence, include quantitative descriptions and/or comparisons.
Conclusions – State new and/or important feature of the study, and conclusions drawn from it
Abbreviations, acronyms, and symbols should be defined the first time they are used. Place the abbreviation in parentheses after the full word.
Use generic names of drugs.
Proprietary and/or financial interests in any products (or competing products) described in the abstract must be disclosed.
The Scientific Program Subcommittee reserves the right to accept or reject the abstracts submitted for platform or poster presentation as it deems appropriate.

Young Neuro-Ophthalmologist (YNO)

YNO are young neuro-ophthalmologist or neuro-Ophthalmology fellows practicing in the Asia who are below 45 years old at the time of ASNOS 2022 Congress. All authors wishing to participate in the YNO competition must submit their abstract through the 11th ASNOS 2022 Abstract Submission site, indicate their interest on the “Young Neuro-Ophthalmologist” section of the site

Platform Presentation (Free Paper)

The speaker will be given 7 minutes to present his/her paper and 3 minutes to answer questions from the audience. Include relevant financial disclosures at the beginning of the presentation.

*Abstracts that are not accepted by the referees for Free paper (Oral Presentation) will automatically be considered as Poster Presentation.

DECLARATION OF CONSENT

When you submit your abstract, you will be asked to tick the following declarations:

I confirm that I previewed this abstract and that all information is correct not previously presented at other international meeting as an oral and/or poster presentation, or previously published in a journal. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
Submission of the abstract constitutes my consent to publication.

I confirm that I previewed this abstract and that all information is correct not previously presented at other international meeting as an oral and/or poster presentation, or previously published in a journal. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
Submission of the abstract constitutes my consent to publication.

ABSTRACT REVISION & ACCEPTANCE

Acknowledgement of the receipt of abstract submission will be sent to the Presenting author’s email address upon submission. The Presenting Author will receive all correspondence regarding the abstract status, presentation type, date and time, via the email that is provided in the abstract submission.

The decision of Scientific Program Committee on abstract acceptance is final, while author’s preferences for oral or poster presentations will be considered. The committee may offer an alternative format.

Should there be any inquiry, please do not hesitate to contact The 11th Asian Neuro-Ophthalmology Society Congress Committee at asnos@acs-asnos-rcopt.com